Sustained Settlement-Level Pressure
ImmunityBio (IBRX) has been identified on the latest threshold list, indicating sustained short-selling pressure. The stock has maintained a short volume ratio exceeding 50% for five consecutive trading days, a clear signal of persistent bearish flow. This data, derived from the FINRA Consolidated NMS short-volume file, highlights that the stock is experiencing significant selling pressure that is not merely intraday noise but a multi-day trend.
Risk Factors
With a borrow fee currently hovering around 0.6% and a short interest of 30.5%, the stock is showing signs of being a potential candidate for a squeeze if the short volume ratio continues to climb. The combination of high short volume and a days-to-cover ratio of 7.7 suggests that the market is heavily positioned against the stock, making it a high-risk, high-reward play for traders monitoring institutional sentiment.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.